Cipla Limited
CIPLA
Peringkat dalam Saham
#1818
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Harga Saham
$14.61
Kapitalisasi Pasar
$11.80B
Perubahan (1 hari)
-0.12%
Perubahan (1 tahun)
-18.47%
Negara
IN
Perdagangan Cipla Limited (CIPLA)
Kategori
Healthcare
Riwayat hasil dividen untuk Cipla Limited (CIPLA)
Hasil dividen (TTM) dari Cipla Limited (simbol saham: CIPLA) per 2024-03-31: 0.57%
Rata-rata hasil dividen selama 5 tahun terakhir: 0.50%
Rata-rata hasil dividen selama 5 tahun terakhir: 0.50%
Riwayat hasil dividen untuk Cipla Limited (CIPLA) dari 2004 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Mengubah |
|---|---|---|
| 2026 (TTM) | 0.98% | 8.89% |
| 2025 | 0.90% | 57.89% |
| 2024 | 0.57% | 1.79% |
| 2023 | 0.56% | 14.29% |
| 2022 | 0.49% | 0.00% |
| 2021 | 0.00% | -100.00% |
| 2020 | 1.66% | 191.23% |
| 2019 | 0.57% | 62.86% |
| 2018 | 0.35% | 2.94% |
| 2017 | 0.34% | -12.82% |
| 2016 | 0.39% | 39.29% |
| 2015 | 0.28% | -46.15% |
| 2014 | 0.52% | 0.00% |
| 2013 | 0.52% | -21.21% |
| 2012 | 0.66% | -24.14% |
| 2011 | 0.87% | 50.00% |
| 2010 | 0.58% | -36.26% |
| 2009 | 0.91% | 0.00% |
| 2008 | 0.91% | 7.06% |
| 2007 | 0.85% | 60.38% |
| 2006 | 0.53% | -54.70% |
| 2005 | 1.17% | 37.65% |
| 2004 | 0.85% | 0.00% |
Hasil dividen (TTM) untuk perusahaan serupa atau pesaing
| Perusahaan | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
DE
|
|
| 0.00% |
DE
|
|
| 0.00% |
JP
|
|
| 0.00% |
CH
|
|
| 0.91% |
IN
|
